

OPEN

The expression of the long *NEAT1_2* isoform is associated with human epidermal growth factor receptor 2-positive breast cancers

Erik Knutsen¹, Seyed Mohammad Lellahi¹, Miriam Ragle Aure², Silje Nord², Silje Fismen^{3,23}, Kenneth Bowitz Larsen¹, Marta Tellez Gabriel¹, Annica Hedberg¹, Sunniva Stordal Bjørklund², Oslo Breast Cancer Research Consortium (OSBREAC)^{4†}, Anna Mary Bofin⁵, Gunhild Mari Mælandsmo⁶, Therese Sørli², Elin Synnøve Mortensen^{1,3} & Maria Perander^{1*}

The long non-coding RNA *NEAT1* locus is transcribed into two overlapping isoforms, *NEAT1_1* and *NEAT1_2*, of which the latter is essential for the assembly of nuclear paraspeckles. *NEAT1* is abnormally expressed in a wide variety of human cancers. Emerging evidence suggests that the two isoforms have distinct functions in gene expression regulation, and recently it was shown that *NEAT1_2*, but not *NEAT1_1*, expression predicts poor clinical outcome in cancer. Here, we report that *NEAT1_2* expression correlates with HER2-positive breast cancers and high-grade disease. We provide evidence that *NEAT1_1* and *NEAT1_2* have distinct expression pattern among different intrinsic breast cancer subtypes. Finally, we show that *NEAT1_2* expression and paraspeckle formation increase upon lactation in humans, confirming what has previously been demonstrated in mice.

The long non-coding RNA (lncRNA) *NEAT1* (Nuclear Paraspeckle Assembly Transcript 1) has recently gained considerable attention as it is abnormally expressed in human diseases, including cancer and neurodegenerative disorders. The *NEAT1* gene is transcribed into two isoforms, *NEAT1_1* of 3.7 kb and *NEAT1_2* of 22.3 kb, where *NEAT1_1* completely overlaps with the 5' end of *NEAT1_2*¹. *NEAT1_2* is essential for the assembly of paraspeckles, dynamic nuclear ribonucleoprotein complexes that phase-separate from the nucleoplasm to form liquid drop-like structures^{2–7}. In contrast, *NEAT1_1* expression is not sufficient to induce paraspeckle formation, and recent reports suggest that *NEAT1_1* can localize to structures that are distinct from paraspeckles^{7,8}. *NEAT1* expression and paraspeckle formation are upregulated in response to a variety of cellular stressors including mitochondrial stress, proteasome inhibition, oncogene-induced replication stress, hypoxia, heat shock, and viral infections^{9–18}. It is now generally accepted that *NEAT1* and paraspeckles regulate gene expression at both transcriptional and post-transcriptional levels by acting as hubs that sequester specific gene regulatory proteins and mRNAs^{16–20}. Several lines of evidence suggest that *NEAT1* and paraspeckles play critical roles in stress response pathways in general, and at specific developmental stages. *NEAT1* knockout mice display compromised mammary gland development and corpus luteum formation^{21,22}. Moreover, it was recently shown that maternal and zygotic *NEAT1*-depletion frequently led to early developmental arrest at the 16- or 32-cell stage in mouse embryonic cells²³.

Cancer cells are exposed to a variety of extrinsic and intrinsic stressors like hypoxia, proteotoxicity, DNA damage, and reactive metabolic intermediates²⁴. Such malignancy-associated stress has been shown to induce *NEAT1* expression and paraspeckle formation *in vivo*^{15,16}. *NEAT1* levels are elevated in hypoxic regions of breast cancer cell line xenografts, and skin tumors induced by genotoxic stress in mice, display increased *NEAT1*

¹Department of Medical Biology, Faculty of Health Sciences, UiT – The Arctic University of Norway, Tromsø, Norway.

²Department of Cancer Genetics, Institute for Cancer Research, The Norwegian Radium Hospital, Oslo University Hospital, Oslo, Norway. ³Department of Clinical Pathology, University Hospital of North Norway, Tromsø, Norway.

⁴www.osbreac.no, Oslo, Norway. ⁵Department of Clinical and Molecular Medicine, Norwegian University of Science and Technology, Trondheim, Norway. ⁶Department of Tumor Biology, Institute for Cancer Research, The Norwegian Radium Hospital, Oslo University Hospital, Oslo, Norway. ²³Silje Fismen is deceased. [†]A comprehensive list of consortium members appears at the end of the paper. *email: maria.perander@uit.no

expression and paraspeckle formation^{15,16}. In consistence with these observations, *NEAT1* is overexpressed in many cancers^{15,16,25,26}. In most cases, *NEAT1* expression is associated with aggressive disease and poor clinical outcomes^{15,16,25,26}.

Breast cancer is the most common type of cancer in women and covers a broad spectrum of different malignant neoplasms with clinical and genomic heterogeneity^{27,28}. In clinical diagnosis, breast cancer is classified according to histological grade, Ki-67 proliferative index, and to the expression of hormone and growth factor receptors estrogen receptor (ER), progesterone receptor (PgR), and human epidermal growth factor receptor 2 (HER2). The classification of breast cancer has been stratified by gene expression profiling leading to the identification of a 50-gene signature (PAM50) that groups breast cancer into luminal A, luminal B, HER2-enriched, basal-like, and normal-like intrinsic subtypes^{29–31}. Several studies have demonstrated that *NEAT1* is required for proliferation and survival of breast cancer cell lines^{12,16,21,32–35}. Moreover, *NEAT1* is frequently overexpressed in breast tumor samples compared to adjacent normal tissue and is associated with poor overall survival^{16,34–37}. Recently, genomic analyses of 360 primary breast tumors showed that the core promoter of the *NEAT1* gene is frequently mutated in cancer and most of these mutations are associated with loss of expression in *in vitro* assays³⁸. In addition, focal deletions within the *NEAT1* gene were found in 8% of breast cancers, and mutations are frequently found in the exonic region^{38,39}. This suggests that *NEAT1* expression might either protect or enhance cancer initiation and progression dependent on tumor stage. Moreover, a growing body of experimental evidence shows that the two *NEAT1* isoforms have distinct physiological functions^{40,41}. Therefore, it is important to address the relative contribution of *NEAT1_1* and *NEAT1_2* in cancer progression.

In this study, we have examined the relationship between *NEAT1_2* expression and breast cancer subtypes by performing RNA-FISH analyses on core needle biopsies using probes solely recognizing the *NEAT1_2* isoform. We report that *NEAT1_2* expression associates with HER2-positive breast cancers, and with high tumor grade. This is verified by *in silico* analyses of microarray data from three independent breast cancer cohorts showing that *NEAT1_2* is most highly expressed in luminal B and HER2-enriched cancers. Interestingly, we present evidence suggesting that *NEAT1_1* expression shows a distinct distribution among breast cancer subtypes compared to *NEAT1_2*, being highest in ER-positive luminal A and luminal B cancers. This indicates that the relative expression of *NEAT1_1* versus *NEAT1_2* varies among the different breast cancer subclasses. Finally, we report that *NEAT1_2* and paraspeckle formation are induced *in vivo* in human luminal epithelial cells during lactation.

Results

***NEAT1_2* expression is associated with high tumor grade and HER2 positive breast cancers.**

The *NEAT1_2* isoform is essential for the assembly of paraspeckles that regulate the expression of specific genes at certain cellular circumstances^{1,16–20}. Recently, it was shown that the expression of *NEAT1_2*, but not *NEAT1_1*, predicts progression-free survival of ovarian cancer treated with platinum-based chemotherapy¹⁵. This prompted us to specifically investigate the expression of *NEAT1_2* in breast cancer. To determine the relationship between breast cancer subtypes and both *NEAT1_2* expression and associated paraspeckle formation, we performed *NEAT1_2*-specific RNA-FISH analyses on 74 formalin-fixed paraffin-embedded needle biopsies taken from females at the time of diagnosis of breast cancer. The samples were selected to represent cancers pathologically classified as luminal A (n = 23), luminal B (n = 29), triple negative/basal-like (n = 14) and HER2-positive (n = 8). We also included 27 non-cancerous breast samples in the study (23 fibroadenomas, 3 mammary reduction, and 1 *BRCA1* prophylactic mastectomy). Cancer cells were identified by experienced pathologists, and *NEAT1_2* expression was manually scored from “0” to “3” based on the presence and morphology of punctuated nuclear signals corresponding to paraspeckles (Fig. 1a). Samples scored as “1”, “2”, and “3” were defined as *NEAT1_2*-positive. Forty-nine patients (66%) were positive for *NEAT1_2* expression (Fig. 1b). In all cases, the expression was strictly restricted to cancer cells, with no detectable *NEAT1_2* signals in surrounding stromal tissue, infiltrating immune cells, or in unaffected breast tissue. In sharp contrast, only 2 out of 27 benign breast tissue samples were *NEAT1_2*-positive (7.4%), both samples being scored as “1” (Fig. 1b). Clinicopathological characteristics were acquired from each patient and correlated with *NEAT1_2* expression (Table 1). *NEAT1_2* levels significantly associated with tumor grade (Chi square test p = 0.027; Fig. 1c, Table 1), confirming what has previously been reported by others on total *NEAT1*. Interestingly, *NEAT1_2* expression also associated with HER2 positive breast cancers (Chi square test p = 0.042; Fig. 1d, Table 1). To verify these results, we analyzed microarray expression data from 381 breast cancer patients (Oslo2) using data generated by a *NEAT1_2*-specific probe⁴². We confirmed that *NEAT1_2* expression was associated with grade (Kruskal-Wallis test p = 3.169e-08; Fig. 2a) and HER2 status (Wilcoxon Rank-Sum test p = 1.49e-06; Fig. 2b). Intriguingly, we also found that *NEAT1_2* expression was significantly lower in ER-positive tumors compared to ER-negative tumors in this cohort (Wilcoxon Rank-Sum test p = 0.005155; Supplementary Fig. 1). To further determine the relationship between *NEAT1_2* and HER2 expression in the Oslo2 cohort, we investigated the correlation between *NEAT1_2* levels and *ERBB2* copy number and mRNA expression in HER2-positive and HER2-negative cancers. A close to significant positive correlation was found between *NEAT1_2* expression and *ERBB2* copy number (Spearman’s rank correlation R = 0.35, p = 0.074; Fig. 2c, left panel), and a significant positive correlation was found between *NEAT1_2* and *ERBB2* mRNA expression (Spearman’s rank correlation R = 0.56, p = 0.003; Fig. 2d, left panel). As expected, no correlation was found between *NEAT1_2* and *ERBB2* amplification or mRNA expression in HER2-negative cancers (Fig. 2c,d, right panel). Finally, we assessed the expression of *NEAT1_2* by RNA-FISH and RT-qPCR in nine breast cancer cell lines classified according to the expression of hormone- and growth factor receptors into ER/PgR-positive HER2-negative cells (MCF7, T-47D), HER2-positive cells (BT474, HCC1569, SK-BR-3), and triple negative cells (BT549, Hs 578T, MDA-MB-231, MDA-MB-468)⁴³. In consistence with previous reports, the morphology, as well as the number and size of *NEAT1_2*-containing paraspeckles, varied substantially between the different cell lines (Supplementary Fig. 2)⁴⁴. We also observed cell-to-cell variations within each cell line. In general, both the number and size of *NEAT1_2*-containing punctas were hard to determine as they frequently




Figure 1. *NEAT1_2* expression and paraspeckle formation correlate with tumor grade and HER2 expression in breast cancer. (a) RNA-FISH analyses of *NEAT1_2* in formalin-fixed paraffin-embedded needle biopsies from breast cancer and benign samples. *NEAT1_2* expression is scored from “0” to “3” based on punctuated nuclear *NEAT1_2* signals according to the indicated criteria. For tumor samples, only tumor cells were included in the scoring, while for normal samples, only epithelial cells were included. (b) *NEAT1_2* is more highly expressed in tumor versus normal tissue. (c) *NEAT1_2* expression associates with tumor grade. (d) *NEAT1_2* expression associates with HER2 expression. Data are presented as mean (thick black line) \pm standard deviation (thin black lines). Circles represent single patient scores. Statistical significance was calculated using the Mann Whitney test (b) or Chi square test (c) and (d). Data were considered statistically significant when $p \leq 0.05$.

Variable, n(%)		NEAT1_2 expression				p	Total (n = 74)
		0 (n = 25)	1 (n = 20)	2 (n = 23)	3 (n = 6)		
Age at diagnosis	<55	10 (34.5)	8 (27.6)	8 (27.6)	3 (10.3)	0.920	29 (39.2)
	≥55	15 (33.3)	12 (26.7)	15 (33.3)	3 (6.7)		45 (60.8)
Histologic grade	1	10 (55.6)	5 (27.8)	3 (16.7)	0 (0.0)	0.027*	18 (24.3)
	2	8 (34.8)	9 (39.1)	5 (21.7)	1 (4.3)		23 (31.1)
	3	7 (22.2)	6 (18.2)	15 (45.5)	5 (15.2)		33 (44.6)
Tumor type	NST	20 (29.9)	20 (29.9)	22 (32.8)	5 (7.5)	0.156	67 (90.5)
	ILC	3 (100.0)	0 (0.0)	0 (0.0)	0 (0.0)		3 (4.1)
	Other invasive carcinoma ^a	2 (50.0)	0 (0.0)	1 (25.0)	1 (25.0)		4 (5.4)
Tumor diameter ^b	<20 mm	14 (37.8)	12 (32.4)	7 (18.9)	4 (10.8)	0.213	37 (53.6)
	≥20 mm	11 (34.4)	6 (18.8)	13 (40.6)	2 (6.3)		32 (46.4)
Lymph node metastasis ^b	Negative	17 (35.5)	14 (29.2)	13 (27.1)	4 (8.3)	0.990	48 (67.6)
	Positive	8 (34.8)	6 (26.1)	7 (30.4)	2 (8.7)		23 (32.4)
ER	Negative (<1%)	4 (16.7)	7 (29.2)	11 (45.8)	2 (8.3)	0.131	24 (32.4)
	Positive (≥1%)	21 (42.0)	13 (26.0)	12 (24.0)	4 (8.0)		50 (67.6)
PgR	Negative (<1%)	6 (20.7)	8 (27.6)	12 (41.4)	3 (10.3)	0.226	29 (39.2)
	Positive (≥1%)	19 (42.2)	12 (26.7)	11 (24.4)	3 (6.7)		45 (60.8)
HER2	Negative (0, 1+, 2+/no ISH amp)	22 (42.3)	13 (25.0)	15 (28.8)	2 (3.8)	0.042*	52 (70.3)
	Positive (2+/ISH amp, 3+)	3 (13.6)	7 (31.8)	8 (36.4)	4 (18.2)		22 (29.7)

Table 1. Clinicopathological variables and *NEAT1_2* expression in breast cancer screening cohort (n = 74). The Chi square test (χ^2 -value) was used to calculate p-values. ^aTubulolobular carcinoma (n = 1), metaplastic squamous cell carcinoma (n = 1), mucinous carcinoma (n = 1), apocrine carcinoma (n = 1). ^bPatient(s) data missing. *P-value significant. Invasive carcinoma of no special type (NST), invasive lobular carcinoma (ILC), *in situ* hybridization (ISH), amplification (amp).

formed clusters. We therefore measured the average intensities of *NEAT1_2* signals per cell in all cell lines (Fig. 2e). Interestingly, HER2-positive BT474 and HCC1569 clearly expressed the highest levels of *NEAT1_2*. Moreover, *NEAT1_2* expression levels in HER2-positive SK-BR-3 cells were only exceeded by those in MCF7 cells. This was confirmed by RT-qPCR analyses using primers specifically amplifying the *NEAT1_2* isoform (Fig. 2f). Generally, results obtained by imaging and RT-qPCR were concordant, only showing deviations for the BT549 cell line. We conclude that high *NEAT1_2* expression is associated with HER2-positive breast cancer and with high-grade disease. Moreover, the presence of *NEAT1_2* and paraspeckles are highly specific for cancer cells, and not present or very lowly expressed in surrounding normal cells or non-cancerous breast epithelial cells.

***NEAT1_2* expression is associated with the HER2-enriched and luminal B breast cancer subtypes.** We demonstrated above that *NEAT1_2* expression associates with HER2-positive breast cancer. HER2 overexpressing cancers are in most cases classified as HER2-enriched or luminal B using the PAM50 gene expression signature identifier. To assess the association between *NEAT1_2* expression and intrinsic breast cancer subtypes, we analyzed microarray gene expression data derived from the Oslo2 cohort described above, and two publicly available breast cancer patient cohorts, METABRIC²⁸ and The Cancer Genome Atlas (TCGA)⁴⁵. Patients were subtyped using the PAM50 algorithm³¹, and only data generated from probes solely recognizing the *NEAT1_2* isoform were considered. In all three cohorts, *NEAT1_2* was most highly expressed in breast cancers classified as HER2-enriched and luminal B, but with different intrinsic distributions (HER2-enriched > luminal B in Oslo2 and METABRIC; luminal B > HER2-enriched in TCGA) (Fig. 3a–c). Luminal A breast cancers had the lowest expression of *NEAT1_2* in all three cohorts. Taken together, these results are in accordance with the observed correlation between *NEAT1_2* expression and HER2-status.

***NEAT1_1* expression is highest in luminal A and luminal B breast cancers.** Previous reports have demonstrated that the *NEAT1* gene is transcriptionally activated by ER α in both prostate and breast cancer, and the transcript participates in a gene repressor complex that induces epithelial-mesenchymal transition (EMT) in a mouse model of ER-positive breast cancer^{25,36}. Here, we have found that the expression of the long *NEAT1_2* isoform is lower in ER-positive compared to ER-negative tumors in the Oslo2 breast cancer cohort (Supplementary Fig. 1). This potential discrepancy made us analyze the expression of total *NEAT1* using microarray data derived from probes binding to both *NEAT1_1* and *NEAT1_2* from the TCGA cohort. Interestingly, total *NEAT1* expression showed a different distribution among the PAM50 subtypes compared to *NEAT1_2*, being most highly expressed in luminal A, luminal B, and normal-like cancers (Fig. 4). *NEAT1_1* is, as opposed to *NEAT1_2*, a polyadenylated transcript. To more specifically investigate the expression of *NEAT1_1* in breast cancer, we analyzed polyA-selected RNA-sequencing data from the TCGA breast cancer cohort. We only extracted data from samples that hardly displayed any mapping of fragments to the unique *NEAT1_2* region (<1.0 FPKM (Fragments Per Kilobase Million)) (Fig. 5a). Patients were then subtyped according to the PAM50 classifier, and ER and HER2 status were extracted. *NEAT1_1* showed a similar distribution among the PAM50 subtypes as total *NEAT1*, being highest in luminal A and luminal B breast cancers (Fig. 5b). In line with this, *NEAT1_1* expression




Figure 2. The association between *NEAT1_2* expression and HER2 status is verified in an independent breast cancer cohort and in breast cancer cell lines. **(a)** *NEAT1_2* expression was analyzed in microarray gene expression profiling data from patients in the Oslo2 cohort and correlated to tumor grade. The Kruskal-Wallis test was used to calculate whether any groups are significantly different from each other and Wilcoxon Rank-Sum test was used in post-testing for significant differences between pairs of groups. (** $p \leq 0.0001$; * $p \leq 0.01$). **(b)** *NEAT1_2* expression levels were correlated to HER2 status. The Wilcoxon Rank-Sum test was used to test for significant differences between the groups. **(c)** and **(d)** *NEAT1_2* expression positively correlates with *ERBB2* copy number (c) and *ERBB2* mRNA expression (d) in HER2-positive, but not in HER2-negative, patients. Correlation was calculated using Spearman's rank correlation. **(e)** Breast cancer cell lines were subjected to *NEAT1_2* RNA-FISH and *NEAT1_2*-specific signal intensity per nucleus in at least 250 cells was quantitated. Data are given as mean (thick black line) \pm standard deviation (thin black lines). Circles represent single cell intensities. The Kruskal-Wallis test was used to calculate whether any groups are significantly different from each other. **(f)** RNA was isolated from breast cancer cell lines and the expression of *NEAT1_2* was determined by RT-qPCR. The geometric means of *B2M*, *GAPDH*, and *RPLP0* were used for normalization. The mean value \pm standard deviation of three biological independent experiments is presented as fold change relative to MCF7 *NEAT1_2* expression. Statistical significance was calculated using the Kruskal-Wallis test. Data were considered statistically significant when $p \leq 0.05$.

clearly associated with ER-positive tumors (Wilcoxon Rank-Sum test $p = 9.2\text{e-}37$; Fig. 5c). Finally, we found no association between *NEAT1_1* and HER2 expression (Wilcoxon Rank-Sum test $p = 0.398$; Fig. 5d). To conclude, our data clearly indicate that the relative expression of *NEAT1_1* versus *NEAT1_2* varies among different breast cancer subclasses.




Figure 3. *NEAT1_2* is most highly expressed in HER2-enriched and luminal B intrinsic breast cancer subtypes in three independent cohorts. (a–c) *NEAT1_2* expression in PAM50 intrinsic breast cancer subtypes from patients of the Oslo2 (a), METABRIC (b), and TCGA (c) breast cancer cohorts. Subtypes were determined using the PAM50 algorithm. The Kruskal–Wallis test was used to calculate whether any groups are significantly different from each other and Wilcoxon Rank-Sum test was used in post-testing for significant differences between pairs of groups. (**** $p \leq 0.0001$; *** $p \leq 0.001$; ** $p \leq 0.01$; * $p \leq 0.05$; ns, $p > 0.05$).

***NEAT1_2* expression is upregulated in human breast tissue during lactation.** We have demonstrated that *NEAT1_2* is rarely expressed in normal human breast tissue. *NEAT1* female knock-out mice display compromised mammary gland development during puberty and pregnancy, and fail to lactate due to impaired proliferation of luminal alveolar cells²². This suggests that *NEAT1* has an important function in mammary gland development, and during pregnancy and lactation. In order to investigate if *NEAT1_2* is expressed during lactation in humans, we analyzed eight needle biopsies taken from females with lactation-related benign changes in the mammary gland. Importantly, 75% ($n = 6$) of the lactating breast tissue samples were positive for *NEAT1_2* using the same scoring scheme as above (Figs. 1a and 6a). Of note, we also had access to one sample from a pregnant woman, which was scored as *NEAT1_2* positive (score 2). In both the lactating tissue and the breast tissue from the pregnant female, the expression of *NEAT1_2* was restricted to the luminal breast epithelial cells (Fig. 6b).




Figure 4. Total *NEAT1* is most highly expressed in the luminal subtypes in the TCGA breast cancer cohort. Expression of total *NEAT1* in PAM50 intrinsic breast cancer subtypes was determined using data generated from four independent microarray probes in the TCGA cohort. The Kruskal-Wallis test was used to calculate whether any groups are significantly different from each other and Wilcoxon Rank-Sum test was used in post-testing for significant differences between pairs of groups. (**** $p \leq 0.0001$; *** $p \leq 0.001$; ** $p \leq 0.01$; * $p \leq 0.05$; ns, $p > 0.05$).

Discussion

The lncRNA *NEAT1* locus is conserved in mammalian species and encodes two overlapping transcripts, *NEAT1_1* and *NEAT1_2*, of which the latter is essential for the assembly of paraspeckles⁴. Early analyses in mice indicated that whereas *NEAT1_1* is ubiquitously expressed, the expression pattern of *NEAT1_2*, and thus the presence of paraspeckles, is more restricted⁵. Emerging evidence now suggests that *NEAT1_2* and paraspeckles play critical roles in orchestrating specific gene expression upon cellular stress and at specific developmental stages^{9–18}. Importantly, it was recently shown that the expression of *NEAT1_2*, but not total *NEAT1*, was associated with aggressive cancers¹⁵. Here, we have specifically analyzed the expression of *NEAT1_2* in breast cancer. By performing RNA-FISH on 74 breast cancer needle biopsies, we found that *NEAT1_2* expression and paraspeckle formation associated with HER2-positive cancers. We verified this by inspecting microarray data generated by a *NEAT1_2*-specific probe from a cohort of 381 patients. Moreover, we found that *NEAT1_2* is highly expressed in HER2-positive compared to HER2-negative breast cancer cell lines. Finally, in three different breast cancer cohorts, *NEAT1_2* expression associated with HER2-enriched and luminal B PAM50 intrinsic subtypes.

Around 15–20% of all breast cancers overexpress the HER2 receptor, many of them due to the amplification of the *ERBB2* gene on chromosome 17, and HER2-driven cancers are generally aggressive^{46,47}. The HER2 receptor is




Figure 5. *NEAT1_1* is most highly expressed in the luminal breast cancer subtypes in the TCGA RNA-Seq cohort. **(a)** *NEAT1* common region FPKM (Fragments Per Kilobase Million) is plotted against *NEAT1_2* specific-region FPKM for each patient. Each dot represents one patient. Samples with more than 1 FPKM for the *NEAT1_2*-specific region (red dots) were excluded from further analysis. **(b)** *NEAT1_1* is most highly expressed in luminal A and luminal B tumors. The Kruskal-Wallis test was used to calculate whether any groups are significantly different from each other and Wilcoxon Rank-Sum test was used in post-testing for significant differences between pairs of groups. **(c)** *NEAT1_1* expression associates with ER expression status. **(d)** *NEAT1_1* expression does not associate with HER2 status. Statistical significance was calculated in **(c)** and **(d)** using Wilcoxon Rank-Sum test. Data were considered statistically significant when $p \leq 0.05$. (**** $p \leq 0.0001$; *** $p \leq 0.001$; ** $p \leq 0.01$; * $p \leq 0.05$; ns, $p > 0.05$).

an orphan member of the epidermal growth factor receptor family that upon overexpression forms homodimers or heterodimers with either EGFR, HER3, or HER4, which elicit signaling pathways, including the MEK-ERK and PI3-kinase-Akt pathways, that drive tumorigenesis^{46,47}. *NEAT1* expression is generally regulated at the transcriptional level, and it is reasonable to assume that HER2-signaling leads to the activation of the *NEAT1* promoter. Indeed, *NEAT1* transcription is activated by a series of stress-induced transcription factors including HIF2 α , HSF1, and NF- κ B, which have been shown to be constitutively upregulated or activated in HER2 overexpressing cells⁴⁸⁻⁵¹. Importantly, *NEAT1* is also a p53 target gene, and oncogenic stress has been shown to upregulate *NEAT1* expression in a p53-dependent manner^{15,52,53}. This might account for the relatively high expression of *NEAT1_2* observed in the wild-type p53 cell line MCF7 (Fig. 2e,f). Recently, it was suggested that high *NEAT1* expression is associated with good prognosis in p53 wild-type breast cancers⁵⁴. However, p53 is frequently mutated in HER2-positive cancers⁴⁵, and HCC1569 cells, which express the largest amount of *NEAT1_2* among the cell lines included in this study, carry a p53 nonsense mutation⁵⁵. The relationship between p53 mutational status, HER2, and *NEAT1* expression in breast cancer should be a subject of future research.

As *NEAT1_1* and *NEAT1_2* are transcribed from the same promoter, it is logical to hypothesize that the expression pattern of *NEAT1_1* mirrors that of *NEAT1_2*. Importantly, by analyzing microarray data derived from probes binding to both *NEAT1* isoforms and polyA-enriched RNA-sequencing data, we found that *NEAT1_1* expression showed a different distribution among the PAM50 subtypes compared to *NEAT1_2*.




Figure 6. *NEAT1_2* is expressed in lactating breast tissue. **(a)** RNA-FISH analyses of *NEAT1_2* in breast tissue from lactating females ($n = 8$). *NEAT1_2* expression is scored from “0” to “3” based on punctuated nuclear *NEAT1_2* signals according to the indicated criteria in Fig. 1a. Data are shown as mean (thick black line) \pm standard deviation (thin black lines). Circles represent single patient scores. **(b)** RNA-FISH images from three lactating females. *NEAT1_2* is visualized in green, and DAPI (blue) was used to stain the nuclei. White asterisks visualize some of the lumens within the mammary glands.

Whereas *NEAT1_2* is most highly expressed in HER2-enriched and luminal B cancers, *NEAT1_1* expression is highest in ER-positive luminal A and luminal B cancers. Thus, our analyses strongly suggest that the relative levels of *NEAT1_1* versus *NEAT1_2* vary in different breast cancer subtypes. Previous reports have shown that *NEAT1* is transcriptionally activated by ER α in both prostate and breast cancer cell lines^{25,36}. Recently, Li *et al.* found that *NEAT1* participates in a transcriptional repressor complex with FOXN3 and SIN3A in ER-positive breast cancer cells³⁶. The complex induces EMT *in vitro* by downregulating GATA3 expression and promotes metastasis in mouse models of ER-positive breast cancer. The FOXN3-*NEAT1*-SIN3A complex also binds to and represses the promoter of the *ESR1* gene indicating the presence of a negative feed-back regulatory mechanism. Importantly, the authors suggest that the FOXN3-*NEAT1*-SIN3A complex functions independently of paraspeckles and that it is the *NEAT1_1* isoform that participates in this complex. In line with this, Chakravarty *et al.* demonstrated that *NEAT1_1*, but not *NEAT1_2*, binds directly to histone H3 and recruits ER α to the *PSMA* promoter in prostate cancer cell lines²⁵. We hypothesize that in ER-positive cancers, *NEAT1_1* contributes to the tumorigenic phenotype by directly participating in transcriptional regulation at the chromatin level. This mechanism might be less important in HER2-positive cancers where increased *NEAT1_2* levels and paraspeckle formation are required for their adaptation to malignancy-associated stress and survival. A recent study of pan-cancer tissue microarrays, indeed showed that 65% of human carcinomas displayed increased number of paraspeckles compared to non-malignant tissue¹⁵. More importantly, the same authors reported that the expression of *NEAT1_2*, but not total *NEAT1*, predicted progression-free survival of ovarian cancer treated with platinum-based chemotherapy. *NEAT1_2* is produced when the polyadenylation signal required for the formation of *NEAT1_1*, is suppressed by a hnRNPK-dependent mechanism^{7,56}. Moreover, key paraspeckle-associated proteins including NONO and SFPQ bind to and stabilize *NEAT1_2*⁶. Further experiments should be undertaken to determine their expression and subcellular localization in HER2-positive breast cancers, as well as in other cancers.

We have found that *NEAT1_2* is not expressed in normal tissue surrounding breast cancer cells at levels that can be detected by RNA-FISH. Furthermore, only 7.4% of benign breast tissue samples were *NEAT1_2* positive. Murine *Neat1* is critical for normal development of the mammary gland, and *Neat1_2* and paraspeckles were detected in 30–50% of K8/K18-positive luminal cells in adult mice²². The number of *Neat1_2* positive cells increased upon pregnancy and lactation. To further inspect *NEAT1* expression pattern in human mammary gland development, we performed RNA-FISH on 8 benign breast tissue samples taken from lactating women. We detected *NEAT1_2* and paraspeckles in 6 samples (75%). Our data strongly supports the observations done in mice and suggests that *NEAT1_2* and paraspeckle formation are upregulated during lactation also in humans. However, it remains to be determined at which stage in pregnancy *NEAT1_2* is upregulated. As *Neat1* knockout mice display compromised proliferation of luminal alveolar epithelial cells during pregnancy²², it is reasonable to hypothesize that elevated *NEAT1_2* levels are required for pregnancy-induced expansion of the epithelial

compartment in humans as well. Alternatively, *NEAT1_2* might be upregulated during the differentiation of luminal alveolar cells into milk-secreting cells. The epithelium of the adult mammary gland is interspersed with mammary stem cells and progenitor cells⁵⁷. In the future, experiments should be undertaken to determine the expression status of *NEAT1* in these cells, as this would shed light on the function of *NEAT1* in both postnatal mammary gland development and breast cancer.

We provide evidence that *NEAT1_2* expression associates with HER2-positive cancers and suggest that the relative expression of *NEAT1_1* versus *NEAT1_2* varies in breast cancer subtypes. The overlapping nature of the *NEAT1_1* and *NEAT1_2* hampers isoform-specific analyses and might affect the interpretation of expression data. *NEAT1_2* is not polyadenylated, which needs to be taken into account when analyzing polyA-enriched RNA-sequencing data. It should also be noted that RNA stability is a technical challenge when analyzing *NEAT1_2* expression in formalin fixed paraffin embedded patient samples by RNA-FISH. Nevertheless, both *NEAT1_1* and *NEAT1_2* are likely to contribute to breast cancer tumorigenesis, but through different mechanisms. The highly tumor-specific expression of *NEAT1_2* in breast cancer, makes it a promising target for future therapeutic intervention.

Methods

Cell culture. BT474 (ATCC® HTB-20™), BT549 (ATCC® HTB-122™), HCC1569 (ATCC® CRL-2330™), Hs 578T (ATCC® HTB-126™), MDA-MB-231 (ATCC® HTB-26™), MDA-MB-468 (ATCC® HTB-132™), MCF7 (ATCC® HTB-22™), SK-BR-3 (ATCC® HTB-30™), and T-47D (ATCC® HTB-133™) cells were all purchased from the American Type Culture Collection (ATCC). BT474, BT549, HCC1569, MDA-MB-231, MDA-MB-468, SK-BR-3, and T-47D cells were cultured in RPMI 1640 (Sigma-Aldrich) supplemented with 10% Fetal bovine serum (FBS) (Biochrom) and 1% penicillin-streptomycin (Sigma-Aldrich). BT549 cells were grown in the presence of 1.0 µg/ml insulin (Sigma-Aldrich) and T-47D cells were grown in the presence of 6.0 µg/ml insulin. Hs 578 T cells were cultured in Dulbecco's Modified Eagle's Medium (DMEM; Sigma-Aldrich) supplemented with 10% FBS, 1% penicillin-streptomycin, and 10.0 µg/ml insulin. MCF7 cells were cultured in Minimum Essential Medium Eagle (MEM; Sigma-Aldrich) supplemented with 10% FBS, 1% penicillin-streptomycin, and 10.0 µg/ml insulin. All cell lines were incubated in a 5% CO₂ humidified incubator at 37 °C.

RNA isolation, cDNA synthesis, and RT-qPCR. Cells were lysed in 300 µl Tri Reagent (Zymo Research) and heated for 10 min at 55 °C in order to prevent *NEAT1* from being trapped in the protein phase during isolation⁴⁴. Total RNA was isolated with Direct-zol RNA MiniPrep (Zymo Research) according to the manufacturer's recommendation. RNA concentration was measured by NanoDrop 2000 (Thermo Fisher Scientific). cDNA synthesis of total RNA was performed with SuperScript™ IV Reverse Transcriptase (ThermoFisher Scientific). 2.5 µM of random hexamer primer (ThermoFisher Scientific) and approximately 400 ng of template were used for the reaction. Total RNA was denatured at 65 °C for 5 min, and cDNA was synthesized at 50 °C for 10 min.

For RT-qPCR, cDNA was mixed with FastStart Essential DNA Green Master (Roche Life Science) and 0.25 µM forward and reverse primer. All primer sequences are provided in Supplementary Table 1. The LightCycler® 96 was used for quantification, and the $\Delta\Delta C_q$ -method was used to calculate fold change using the geometric mean of *GAPDH*, *B2M*, and *RPLPO* as internal reference.

RNA-FISH of cells and FFPE tissue. Stellaris® *NEAT1* RNA FISH probes recognizing the *NEAT1_2* isoform (SMF-2037-1 conjugated with Quasar® 670) was purchased from LGC Biosearch Technologies. Preparation of cells and FFPE sections, hybridization, and mounting were performed according to the Stellaris® RNA FISH Probes manuals. In brief, cells were seeded onto circular coverslips in 12-well dishes and allowed to attach for 2–3 days. The cells were fixed with 4% formaldehyde and permeabilized with 70% EtOH. Hybridization was done at 37 °C in a humidifying chamber for at least 4 hours. FFPE tissue sections were cut fresh and placed at 60 °C for 45 min before being deparaffinized with xylene. Here, hybridization was performed overnight. Vectashield® Mounting Medium containing DAPI was used for mounting of both cells and FFPE sections. Images were generated using a Zeiss LSM780 confocal microscope. For cells, 3-dimensional Z-stack images were taken at 40x magnification (seven pictures, with 0.6 µm distance between each picture). Images of FFPE sections were taken at 20x magnification with no Z-stacking. All images were processed using ZEN 2012 (black edition) v8.0. *NEAT1_2* fluorescence was quantified from maximum intensity projections of confocal z-stacks using Fiji⁵⁸ running ImageJ⁵⁹ version 1.52n. An automatic threshold was set in the DAPI channel in order to segment individual nuclei using the wand tool. In some cases, nuclear outlines were manually traced. The average intensity in the *NEAT1_2* channel was then measured for each nucleus.

Clinical samples. Archived FFPE needle biopsies were obtained from the Department of Pathology, University Hospital of North Norway (UNN) with corresponding hematoxylin and eosin (HE) slides from all patients. Samples from 74 patients diagnosed with breast cancer (2012–2018, age range 31–84 years), 27 normal samples (2013–2015, age range 18–68 years), 8 samples from lactating females (2013–2015, age range 25–42), and 1 sample from a pregnant female (2013, age 32) were included in the study. Approval for this study, including dispensation from the requirement of patient consent, was granted by the Norwegian Regional Committee for Medical and Health Research Ethics, approval number 2014/317. We confirm that all experiments were performed in accordance with relevant guidelines and regulations. Histological tumor grade was assessed by the Nottingham Grading System⁶⁰. The samples were classified by pathologists as luminal A (ER+ and/or PgR+, HER2- Ki-67 < 15%), luminal B (ER+ and/or PgR+, HER2- Ki-67 ≥ 15% or ER+ and/or PgR+, HER2+), triple negative/basal-like (ER-, PgR-, HER2-), or HER2-positive (ER-, PgR-, HER2+). The cut off values for ER and PgR were 1%. Tumors with HER2 protein overexpression (IHC 3+) or with *in situ* hybridization (ISH)-detected amplified HER2 gene (IHC 2+/ISH HER2 gene amplification) were considered to be HER2

positive. *NEAT1_2* expression and clinicopathological characteristics were analyzed by the Chi square test (χ^2 -value) using SPSS version 25 (SPSS Inc., Chicago, IL, USA). P-values ≤ 0.05 (two-tailed) were considered statistically significant.

Gene expression analyses in breast cancer cohorts. *NEAT1* gene expression was assessed in three independent breast cancer cohorts; Oslo⁴², METABRIC²⁸, and TCGA⁴⁵. Oslo is a multicentre study of breast cancer patients with primary operable breast cancers enrolled from hospitals in the Oslo (Norway) region (approved by the Norwegian Regional Committee for Medical and Health Research Ethics, approval number 2016/433 and 429-04148)⁴². Gene expression data (GEO accession number GSE80999) were obtained using SurePrint G3 Human GE 8 × 60 K microarrays (Agilent Technologies, Santa Clara, CA, USA) and data were log₂-transformed, quantile-normalized, and hospital-adjusted. Probe A_33_P3263538 covered part of the unique 3' end of *NEAT1_2*. *ERBB2* mRNA expression values were derived from mRNA probes using the median value for the two probes matching this gene symbol (A_23_P89249 and A_33_P3292596). For HER2 copy number analysis, logR values (the log₂-transformed value of the normalized intensity of the SNP) were extracted from raw CEL-files from Genome-Wide Human SNP Array 6.0 (Affymetrix, Santa Clara, CA, USA) using Affymetrix power tools. Segmented copy number values were generated and non-aberrant cell fraction and ploidy was calculated using the Allele-Specific Copy number Analysis of Tumors (ASCAT) package⁶¹. Segmented copy number data (adjusted for non-aberrant cell admixture and ploidy) were log₂-transformed and made probe-centric based on the *ERBB2* mRNA expression array probe location. The METABRIC cohort is composed of 1980 breast cancer patients collected at five different hospitals in the UK and Canada²⁸. Gene expression was assessed using the Illumina HT-12 v3 microarray and downloaded from the European Genome-phenome Archive (EGA) data portal. The data were log₂-transformed. Probe ILMN_1675354 covered part of the unique 3' end of *NEAT1_2*. Gene expression levels for the Caucasian fraction of the TCGA cohort (n = 526) were assayed by Agilent 244 K Custom Gene Expression G4502A-07-3⁴⁵. The data were log₂-transformed after normalization. The probe A_32_P206561 covered parts of the unique 3' end of *NEAT1_2*, while probes A_32_P1036, A_32_P1037, A_24_P566917, and A_24_P566916 covered parts of the common region between *NEAT1_1* and *NEAT1_2*. For analysis of RNA-Seq data from TCGA, bam files aligned to GRCh38 were downloaded from <https://gdc.cancer.gov/>. Reads mapping to the *NEAT1* common region (Chr11: 65422798-65426532) and the *NEAT1_2* specific region (Chr11: 65426533-65445540) were counted using the featureCounts function of the Subread package specified with the -p flag (version 1.6.1)⁶². Fragments spanning the end of the *NEAT1* common region and the start of the *NEAT1_2* specific region were excluded. FPKM was calculated as $[RMg * 10^9]/[RMt * L]$, where RMg are reads mapping to each transcript, L is length of transcripts in bp, and RMt are total number of mapped reads. Samples with *NEAT1_2* specific region FPKM ≥ 1.0 were filtered out, leaving 1065 tumor samples for clinical analysis.

Statistical analysis. GraphPad software version 25 (SPSS Inc., Chicago, IL, USA) was used to analyze the screening cohort (74 breast cancer needle biopsies). Analysis of significance in expression in normal versus tumor tissue was calculated using the Mann Whitney test. For analyses of clinicopathological variables and *NEAT1_2* expression the Chi square test (χ^2 -value) were used. Data were considered statistically significant when $p \leq 0.05$.

For microarray and RNA-Seq expression analyses, statistical analyses were performed in R⁶³. *NEAT1_2*, *NEAT1_1*, and *NEAT1* expression across PAM50 intrinsic subtypes and tumor grade were compared using the non-parametric Kruskal-Wallis test. For HER2 and ER expression comparison between two groups, Wilcoxon Rank-Sum test were used. Post tests between subtypes and grade were done with Wilcoxon Rank-Sum test. Spearman's rank correlation was used for analysis of *ERBB2* copy number and mRNA expression correlation with *NEAT1_2* expression. Data were considered statistically significant when $p \leq 0.05$.

Received: 8 September 2019; Accepted: 21 December 2019;

Published online: 28 January 2020

References

- Hutchinson, J. N. *et al.* A screen for nuclear transcripts identifies two linked noncoding RNAs associated with SC35 splicing domains. *BMC Genomics* **8**, 39, <https://doi.org/10.1186/1471-2164-8-39> (2007).
- Sasaki, Y. T., Ideue, T., Sano, M., Mituyama, T. & Hirose, T. MENepsilon/beta noncoding RNAs are essential for structural integrity of nuclear paraspeckles. *Proc. Natl Acad. Sci. USA* **106**, 2525–2530, <https://doi.org/10.1073/pnas.0807899106> (2009).
- Sunwoo, H. *et al.* MEN epsilon/beta nuclear-retained non-coding RNAs are up-regulated upon muscle differentiation and are essential components of paraspeckles. *Genome Res.* **19**, 347–359, <https://doi.org/10.1101/gr.087775.108> (2009).
- Hirose, T., Yamazaki, T. & Nakagawa, S. Molecular anatomy of the architectural NEAT1 noncoding RNA: The domains, interactors, and biogenesis pathway required to build phase-separated nuclear paraspeckles. *Wiley Interdiscip Rev RNA*, e1545, <https://doi.org/10.1002/wrna.1545> (2019).
- Nakagawa, S., Naganuma, T., Shioi, G. & Hirose, T. Paraspeckles are subpopulation-specific nuclear bodies that are not essential in mice. *J. Cell Biol.* **193**, 31–39, <https://doi.org/10.1083/jcb.201011110> (2011).
- Yamazaki, T. *et al.* Functional Domains of NEAT1 Architectural lncRNA Induce Paraspeckle Assembly through Phase Separation. *Mol. Cell* **70**, 1038–1053 e1037, <https://doi.org/10.1016/j.molcel.2018.05.019> (2018).
- Naganuma, T. *et al.* Alternative 3'-end processing of long noncoding RNA initiates construction of nuclear paraspeckles. *EMBO J.* **31**, 4020–4034, <https://doi.org/10.1038/emboj.2012.251> (2012).
- Li, R., Harvey, A. R., Hodgetts, S. I. & Fox, A. H. Functional dissection of NEAT1 using genome editing reveals substantial localization of the *NEAT1_1* isoform outside paraspeckles. *RNA* **23**, 872–881, <https://doi.org/10.1261/rna.059477.116> (2017).
- Beeharry, Y., Goodrum, G., Imperiale, C. J. & Pelchat, M. The Hepatitis Delta Virus accumulation requires paraspeckle components and affects NEAT1 level and PSP1 localization. *Sci. Rep.* **8**, 6031, <https://doi.org/10.1038/s41598-018-24500-1> (2018).
- Saha, S., Murthy, S. & Rangarajan, P. N. Identification and characterization of a virus-inducible non-coding RNA in mouse brain. *J. Gen. Virol.* **87**, 1991–1995, <https://doi.org/10.1099/vir.0.81768-0> (2006).
- Zhang, Q., Chen, C. Y., Yedavalli, V. S. & Jeang, K. T. NEAT1 long noncoding RNA and paraspeckle bodies modulate HIV-1 posttranscriptional expression. *MBio* **4**, e00596–00512, <https://doi.org/10.1128/mBio.00596-12> (2013).

12. Lellahi, S. M. *et al.* The long noncoding RNA NEAT1 and nuclear paraspeckles are up-regulated by the transcription factor HSF1 in the heat shock response. *J. Biol. Chem.* **293**, 18965–18976, <https://doi.org/10.1074/jbc.RA118.004473> (2018).
13. Ma, H. *et al.* The Long Noncoding RNA NEAT1 Exerts Antihantaviral Effects by Acting as Positive Feedback for RIG-I Signaling. *J. Virol* **91**, <https://doi.org/10.1128/JVI.02250-16> (2017).
14. Wang, Y. *et al.* Genome-wide screening of NEAT1 regulators reveals cross-regulation between paraspeckles and mitochondria. *Nat. Cell Biol.* **20**, 1145–1158, <https://doi.org/10.1038/s41556-018-0204-2> (2018).
15. Adriaens, C. *et al.* p53 induces formation of NEAT1 lncRNA-containing paraspeckles that modulate replication stress response and chemosensitivity. *Nat. Med.* **22**, 861–868, <https://doi.org/10.1038/nm.4135> (2016).
16. Choudhry, H. *et al.* Tumor hypoxia induces nuclear paraspeckle formation through HIF-2 α dependent transcriptional activation of NEAT1 leading to cancer cell survival. *Oncogene* **34**, 4546, <https://doi.org/10.1038/nc.2014.431> (2015).
17. Hirose, T. *et al.* NEAT1 long noncoding RNA regulates transcription via protein sequestration within subnuclear bodies. *Mol. Biol. Cell* **25**, 169–183, <https://doi.org/10.1091/mbc.E13-09-0558> (2014).
18. Imamura, K. *et al.* Long noncoding RNA NEAT1-dependent SFPQ relocation from promoter region to paraspeckle mediates IL8 expression upon immune stimuli. *Mol. Cell* **53**, 393–406, <https://doi.org/10.1016/j.molcel.2014.01.009> (2014).
19. Chen, L. L. & Carmichael, G. G. Altered nuclear retention of mRNAs containing inverted repeats in human embryonic stem cells: functional role of a nuclear noncoding RNA. *Mol. Cell* **35**, 467–478, <https://doi.org/10.1016/j.molcel.2009.06.027> (2009).
20. Prasanth, K. V. *et al.* Regulating gene expression through RNA nuclear retention. *Cell* **123**, 249–263, <https://doi.org/10.1016/j.cell.2005.08.033> (2005).
21. Nakagawa, S. *et al.* The lncRNA Neat1 is required for corpus luteum formation and the establishment of pregnancy in a subpopulation of mice. *Development* **141**, 4618–4627, <https://doi.org/10.1242/dev.110544> (2014).
22. Standaert, L. *et al.* The long noncoding RNA Neat1 is required for mammary gland development and lactation. *RNA* **20**, 1844–1849, <https://doi.org/10.1261/rna.047332.114> (2014).
23. Hupalowska, A. *et al.* CARM1 and Paraspeckles Regulate Pre-implantation Mouse Embryo Development. *Cell* **175**, 1902–1916 e1913, <https://doi.org/10.1016/j.cell.2018.11.027> (2018).
24. Hanahan, D. & Weinberg, R. A. Hallmarks of cancer: the next generation. *Cell* **144**, 646–674, <https://doi.org/10.1016/j.cell.2011.02.013> (2011).
25. Chakravarty, D. *et al.* The oestrogen receptor α -regulated lncRNA NEAT1 is a critical modulator of prostate cancer. *Nat. Commun.* **5**, 5383, <https://doi.org/10.1038/ncomms6383> (2014).
26. Klec, C., Prinz, F. & Pichler, M. Involvement of the long noncoding RNA NEAT1 in carcinogenesis. *Mol. Oncol.* **13**, 46–60, <https://doi.org/10.1002/1878-0261.12404> (2019).
27. Koren, S. & Bentires-Alj, M. Breast Tumor Heterogeneity: Source of Fitness, Hurdle for Therapy. *Mol. Cell* **60**, 537–546, <https://doi.org/10.1016/j.molcel.2015.10.031> (2015).
28. Curtis, C. *et al.* The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups. *Nature* **486**, 346–352, <https://doi.org/10.1038/nature10983> (2012).
29. Perou, C. M. *et al.* Molecular portraits of human breast tumours. *Nature* **406**, 747–752, <https://doi.org/10.1038/35021093> (2000).
30. Sorlie, T. *et al.* Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. *Proc. Natl Acad. Sci. USA* **98**, 10869–10874, <https://doi.org/10.1073/pnas.191367098> (2001).
31. Parker, J. S. *et al.* Supervised risk predictor of breast cancer based on intrinsic subtypes. *J. Clin. Oncol.* **27**, 1160–1167, <https://doi.org/10.1200/JCO.2008.18.1370> (2009).
32. Ke, H. *et al.* NEAT1 is Required for Survival of Breast Cancer Cells Through FUS and miR-548. *Gene Regul. Syst. Bio* **10**, 11–17, <https://doi.org/10.4137/GRSB.S29414> (2016).
33. Jiang, X., Zhou, Y., Sun, A. J. & Xue, J. L. NEAT1 contributes to breast cancer progression through modulating miR-448 and ZEB1. *J. Cell Physiol.* **233**, 8558–8566, <https://doi.org/10.1002/jcp.26470> (2018).
34. Qian, K. *et al.* The long non-coding RNA NEAT1 interacted with miR-101 modulates breast cancer growth by targeting EZH2. *Arch. Biochem. Biophys.* **615**, 1–9, <https://doi.org/10.1016/j.abb.2016.12.011> (2017).
35. Zhao, D., Zhang, Y., Wang, N. & Yu, N. NEAT1 negatively regulates miR-218 expression and promotes breast cancer progression. *Cancer Biomark* **20**, 247–254, <https://doi.org/10.3233/CBM-170027> (2017).
36. Li, W. *et al.* The FOXN3-NEAT1-SIN3A repressor complex promotes progression of hormonally responsive breast cancer. *J. Clin. Invest.* **127**, 3421–3440, <https://doi.org/10.1172/JCI94233> (2017).
37. Shin, V. Y. *et al.* Long non-coding RNA NEAT1 confers oncogenic role in triple-negative breast cancer through modulating chemoresistance and cancer stemness. *Cell Death Dis.* **10**, 270, <https://doi.org/10.1038/s41419-019-1513-5> (2019).
38. Rheinbay, E. *et al.* Recurrent and functional regulatory mutations in breast cancer. *Nature* **547**, 55–60, <https://doi.org/10.1038/nature22992> (2017).
39. Nik-Zainal, S. *et al.* Landscape of somatic mutations in 560 breast cancer whole-genome sequences. *Nature* **534**, 47–54, <https://doi.org/10.1038/nature17676> (2016).
40. Adriaens, C. *et al.* The long noncoding RNA NEAT1_1 is seemingly dispensable for normal tissue homeostasis and cancer cell growth. *RNA* **25**, 1681–1695, <https://doi.org/10.1261/rna.071456.119> (2019).
41. Isobe, M. *et al.* Forced isoform switching of Neat1_1 to Neat1_2 leads to the loss of Neat1_1 and the hyperformation of paraspeckles but does not affect the development and growth of mice. [bioRxiv, 698068](https://doi.org/10.1101/698068), <https://doi.org/10.1101/698068> (2019).
42. Aure, M. R. *et al.* Integrative clustering reveals a novel split in the luminal A subtype of breast cancer with impact on outcome. *Breast Cancer Res.* **19**, 44, <https://doi.org/10.1186/s13058-017-0812-y> (2017).
43. Neve, R. M. *et al.* A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes. *Cancer Cell* **10**, 515–527, <https://doi.org/10.1016/j.ccr.2006.10.008> (2006).
44. Chujo, T. *et al.* Unusual semi-extractability as a hallmark of nuclear body-associated architectural noncoding RNAs. *EMBO J.* **36**, 1447–1462, <https://doi.org/10.15252/embj.201695848> (2017).
45. Cancer Genome Atlas, N. Comprehensive molecular portraits of human breast tumours. *Nature* **490**, 61–70, <https://doi.org/10.1038/nature11412> (2012).
46. Gutierrez, C. & Schiff, R. HER2: biology, detection, and clinical implications. *Arch. Pathol. Lab. Med.* **135**, 55–62, <https://doi.org/10.1043/2010-0454-RAR.1> (2011).
47. Moasser, M. M. The oncogene HER2: its signaling and transforming functions and its role in human cancer pathogenesis. *Oncogene* **26**, 6469–6487, <https://doi.org/10.1038/sj.onc.1210477> (2007).
48. Jarman, E. J. *et al.* HER2 regulates HIF-2 α and drives an increased hypoxic response in breast cancer. *Breast Cancer Res.* **21**, 10, <https://doi.org/10.1186/s13058-019-1097-0> (2019).
49. Schulz, R. *et al.* HER2/ErbB2 activates HSF1 and thereby controls HSP90 clients including MIF in HER2-overexpressing breast cancer. *Cell Death Dis.* **5**, e980, <https://doi.org/10.1038/cddis.2013.508> (2014).
50. Xi, C., Hu, Y., Buckhaults, P., Moskophidis, D. & Mivechi, N. F. Heat shock factor Hsf1 cooperates with ErbB2 (Her2/Neu) protein to promote mammary tumorigenesis and metastasis. *J. Biol. Chem.* **287**, 35646–35657, <https://doi.org/10.1074/jbc.M112.377481> (2012).
51. Cogswell, P. C., Guttridge, D. C., Funkhouser, W. K. & Baldwin, A. S. Jr. Selective activation of NF- κ B subunits in human breast cancer: potential roles for NF- κ B2/p52 and for Bcl-3. *Oncogene* **19**, 1123–1131, <https://doi.org/10.1038/sj.onc.1203412> (2000).

52. Mello, S. S. *et al.* Neat1 is a p53-inducible lincRNA essential for transformation suppression. *Genes. Dev.* **31**, 1095–1108, <https://doi.org/10.1101/gad.284661.116> (2017).
53. Idogawa, M., Ohashi, T., Sasaki, Y., Nakase, H. & Tokino, T. Long non-coding RNA NEAT1 is a transcriptional target of p53 and modulates p53-induced transactivation and tumor-suppressor function. *Int. J. Cancer* **140**, 2785–2791, <https://doi.org/10.1002/ijc.30689> (2017).
54. Idogawa, M., Nakase, H., Sasaki, Y. & Tokino, T. Prognostic Effect of Long Noncoding RNA NEAT1 Expression Depends on p53 Mutation Status in Cancer. *J Oncol* 2019, 4368068, <https://doi.org/10.1155/2019/4368068> (2019).
55. Lacroix, M., Toillon, R. A. & Leclercq, G. p53 and breast cancer, an update. *Endocr. Relat. Cancer* **13**, 293–325, <https://doi.org/10.1677/erc.1.01172> (2006).
56. Naganuma, T. & Hirose, T. Paraspeckle formation during the biogenesis of long non-coding RNAs. *RNA Biol.* **10**, 456–461, <https://doi.org/10.4161/rna.23547> (2013).
57. Fu, N., Nolan, E., Lindeman, G. J. & Visvader, J. E. Stem Cells and the Differentiation Hierarchy in Mammary Gland Development. *Physiol Rev.* <https://doi.org/10.1152/physrev.00040.2018> (2019).
58. Schindelin, J. *et al.* Fiji: an open-source platform for biological-image analysis. *Nat. Methods* **9**, 676–682, <https://doi.org/10.1038/nmeth.2019> (2012).
59. Schneider, C. A., Rasband, W. S. & Eliceiri, K. W. NIH Image to ImageJ: 25 years of image analysis. *Nat. Methods* **9**, 671–675 (2012).
60. Elston, C. W. & Ellis, I. O. Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. *Histopathology* **19**, 403–410 (1991).
61. Van Loo, P. *et al.* Allele-specific copy number analysis of tumors. *Proc. Natl Acad. Sci. USA* **107**, 16910–16915, <https://doi.org/10.1073/pnas.1009843107> (2010).
62. Liao, Y., Smyth, G. K. & Shi, W. featureCounts: an efficient general purpose program for assigning sequence reads to genomic features. *Bioinformatics* **30**, 923–930, <https://doi.org/10.1093/bioinformatics/btt656> (2014).
63. R: A language and environment for statistical computing (R Foundation for Statistical Computing, Vienna, Austria, 2018).

Acknowledgements

This work was supported by Northern Norway Regional Health Authority (HNF1371-17). The publication charges for this article have been funded by a grant from the publication fund of UiT - The Arctic University of Norway.

Author contributions

Conceived and designed the experiments: E.K., M.P. Performed the experiments: E.K., S.M.L., S.F., A.H. Analyzed the data: E.K., M.R.A., S.N., S.F., K.B.L., M.T.G., A.H., S.S.B., E.S.M. and M.P. Contributed reagents/materials/analysis tools: OSBREAC, A.M.B., G.M.M., T.S., E.S.M., M.P. Wrote the paper: E.K., M.P. All authors reviewed the manuscript.

Competing interests

The authors declare no competing interests.

Additional information

Supplementary information is available for this paper at <https://doi.org/10.1038/s41598-020-57759-4>.

Correspondence and requests for materials should be addressed to M.P.

Reprints and permissions information is available at www.nature.com/reprints.

Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.



Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit <http://creativecommons.org/licenses/by/4.0/>.

© The Author(s) 2020

Consortia

Oslo Breast Cancer Research Consortium (OSBREAC)

Jürgen Geisler^{7,8,9}, Solveig Hofvind^{10,11}, Tone F. Bathen¹², Elin Borgen¹³, Anne-Lise Børresen-Dale^{2,8}, Olav Engebråten^{6,8,14}, Øystein Garred¹³, Gry Aarum Geitvik², Anita Langerød², Bjørn Naume^{8,14}, Hege G. Russnes^{2,13}, Ellen Schlichting¹⁵, Ole Christian Lingjærde^{16,17}, Vessela N. Kristensen^{2,8,18}, Helle Kristine Skjerven¹⁹, Thomas Papatomas²⁰, Olaf-Johan Hartman-Johnsen²¹ & Kristine Kleivi Sahlberg²²

⁷Department of Oncology, Akershus University Hospital, Lørenskog, Norway. ⁸Institute for Clinical Medicine, Faculty of Medicine, University of Oslo, Oslo, Norway. ⁹Division of Medicine, Akershus University Hospital, Lørenskog, Norway. ¹⁰Cancer Registry of Norway, Oslo, Norway. ¹¹Oslo and Akershus University College of Applied Sciences, Faculty of Health Science, Oslo, Norway. ¹²Department of Circulation and Medical Imaging, Norwegian University of Science and Technology (NTNU), Trondheim, Norway. ¹³Department of Pathology, Division of Diagnostics and Intervention, Oslo University Hospital, Oslo, Norway. ¹⁴Department of Oncology, Division of Surgery and Cancer and Transplantation Medicine, Oslo University Hospital, Oslo, Norway. ¹⁵Section for Breast- and Endocrine Surgery, Department of Cancer, Division of Surgery, Cancer and Transplantation Medicine, Oslo University Hospital, Oslo, Norway. ¹⁶Centre for Cancer Biomedicine, University of Oslo, Oslo, Norway. ¹⁷Department of Computer Science, University of Oslo, Oslo, Norway. ¹⁸Department of Clinical Molecular Biology and Laboratory Science (EpiGen), Division of Medicine, Akershus University Hospital, Lørenskog, Norway. ¹⁹Breast and Endocrine Surgery, Department of Breast and Endocrine Surgery, Vestre Viken Hospital Trust, Drammen, Norway. ²⁰Department of Pathology, Vestre Viken Hospital Trust, Drammen, Norway. ²¹Østfold Hospital, Østfold, Norway. ²²Department of Research, Vestre Viken Hospital Trust, Drammen, Norway.